EUCTR2020-005648-52-PL进行中（未招募）1 期
A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Tolerability and Pharmacokinetics of Selumetinib after Multiple Doses in Adolescent Children with Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN) - Selumetinib Gastrointestinal Tolerability Study (Selumetinib GI Tolerability and Food Study)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female participants aged = 12 to < 18 years at the time of signing the informed consent.
- •2. All study participants must be diagnosed with (i) NF1 per NIH Consensus Development Conference Statement and (ii) inoperable PN. In addition to PN, participants must have at least 1 other diagnostic criterion for NF1 as defined in protocol.
- •3. Participants must require treatment for NF1 and inoperable PN due to actual symptoms or because of the potential to develop significant clinical complications, as judged by the Investigator, as defined in the protocol.
- •4. Participants who have had prior treatment with any MEKi (including selumetinib) may be considered for inclusion in this study.
- •5. Participants must have a BSA = 1.3 and = 2.5 m2
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Evidence or suspicion of optic glioma, malignant glioma, MPNST, or other cancer requiring treatment with chemotherapy or radiation therapy
- •2. Prior malignancy requiring active treatment (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the participant had been disease free for = 2 years or which would not have limited survival to < 2 years).
- •3. A life-threatening illness, medical condition, organ system dysfunction of laboratory finding which, in the Investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of selumetinib, or put the study outcomes at undue risk.
- •4. Participants with clinically significant cardiovascular disease as listed in the protocol.
- •5. Liver function tests: bilirubin > 1.5 × the ULN for age (with the exception of those with Gilbert syndrome) or AST/ALT > 2 × upper limit of normal.
- •6. Renal Function: Creatinine clearance or radioisotope glomerular filtration rate < 30 mL/min/1.73 m2 or a serum creatinine > 1.2 mg/dL (for participants aged between 12 and 15 years) or > 1.5 mg/dL for participants aged > 15 years).
- •7. Participants with abnormal ophthalmological findings/conditions as listed in the protocol.
- •8. Have any unresolved chronic toxicity, associated with previous therapy for NF1-PN:
- •- Gastrointestinal toxicity of CTCAE Grade 1 or higher.
- •- Have any other unresolved chronic toxicity with CTCAE Grade = 2, except hair changes (such as alopecia or high lightening).
- •9. Participants who have previously been treated with a MEKi (including selumetinib) and either discontinued treatment or required a dose reduction due to toxicity
- •10. Have had recent major surgery within a minimum of 4 weeks prior to starting study intervention, with the exception of surgical placement for vascular access. Have planned major surgery during the treatment period.
- •11. Any multivitamin containing vitamin E must be stopped at least 7 days prior to initiation of selumetinib.
研究者
相似试验
进行中（未招募）
1 期
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children with Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)EUCTR2020-005648-52-ESAstraZeneca AB20
招募中
1 期
Clinical research of filling extraction sockets with selective COX2 inhibitor-containing paste in patients with mandibular wisdom tooth extractions.third molarwisdom tooth extractionD008964JPRN-jRCTs051230162Kakei Yasumasa12
已完成
2 期
A Phase I/II, Single-Arm, Open-label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged >= 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)A genetic disorder characterized by the presence of multiplefrequently symptomless but occasionally malignanttumors formed on a nerve cell sheath1002766410029209NL-OMON56067Astra Zeneca5
尚未招募
1 期
A single-centre, open-label, phase I study to evaluate the diagnostic performance of 89Zirconium-labelled girentuximab (89Zr-TLX250) Position Emission Tomography (PET) in Urothelial Cancer PatientsMetastatic urothelial carcinomaCancer - BladderBladder cancerACTRN12621000411842South Metropolitan Health Services20
进行中（未招募）
1 期
A phase I, open-label, single-centre study to evaluate the absorption, distribution, metabolism and excretion (ADME) of oral [14C]-ibrexafungerp in healthy male subjects after repeat dosingFungal diseaseInfections and InfestationsISRCTN51111674Scynexis (United States)6